Поставщики · Производитель · Промышленная биотехнология и биоматериалы

Kyowa Hakko Bio (Kirin)

Kyowa Hakko Bio (協和発酵バイオ株式会社, Япония) работает в биохимической отрасли: производит функциональные материалы для фармацевтики, медицины и товаров для здоровья.

работает ЯпонияАзия Основана 2008 проверено 2026-10-05

Профиль

Kyowa Hakko Bio Co., Ltd. is a Japan-based specialty fermentation company in Kirin Group, making and selling pharmaceutical raw materials, amino acids, healthcare ingredients, and nucleic-acid products. Core products include amino acids (e.g., L-Arginine, BCAA), nucleic acids such as Citicoline/Cognizin, and human milk oligosaccharides (HMOs); it also markets other healthcare ingredients (e.g., VELOX, IMMUSE, EYEMUSE). It was established October 1, 2008 and is headquartered at Kyowa-cho 1-1, Hofu, Yamaguchi, Japan. Kirin Holdings owns 100% (Kirin is listed on TSE Prime, code 2503); no funding rounds are disclosed. Latest 2025–2026 development: it agreed to carve out its amino acid and HMO businesses to a new company owned via Meihua Holdings, with transfer planned for Q4 2025 after regulatory/pharmaceutical licensing; after transfer, Kyowa Hakko Bio will focus on specialty materials like Citicoline. It remains active through 2025–2026; March 27, 2026 it reported a President transition (President assumed). Scale where known: consolidated employees 1,955 (2024; Sustainability Data 2025); 2024 sales revenue ¥502 million (Kyowa Hakko Bio non-consolidated value shown in the report). Key technology: fermentation via microbial breeding, industrialization (scale-up), and environmental/wastewater treatment.

Sources#

Отрасль: Биопереработка, Пищевые ингредиенты, Промышленная химия, Вода
Темы: Аминокислоты и ферментация глутамата натрия, Органические кислоты и биохимикаты, Дрожжи, ферментация и пищевые ингредиенты
Роль: Производитель — “…BIO CO. LTD. is a Japanese manufacturer of pharmaceutical raw materials and healthcare ingredients. Founded on…”

Биорешения, которые поставляет 0

Пока не указана поставщиком в решениях с доказательствами.

Что предлагают

Дочерние компании: Kyowa Pharma Chemical Co., Ltd. · BioKyowa Inc. · Shanghai Kyowa Amino Acid Co., Ltd. · Thai Kyowa Biotechnologies Co., Ltd. · Kyowa Hakko U.S.A., Inc. · Kyowa Hakko Europe GmbH · Kyowa Hakko Bio Italia S.r.l. · Kyowa Hakko Bio Singapore Pte. Ltd. · Kyowa Hakko (Guangdong) Pharmaceutical Co., Ltd.

Новости и статус 6

2026-10 Последний статус: 1 октября 2026 г. Kyowa Hakko Bio Co., Ltd. завершила передачу дочерней Kyowa Pharma Chemical Co., Ltd. компании Dai Nippon Printing Co., Ltd. ↗ ↗ ↗
2026-10-01 Regarding the Completion of the Share Transfer of Kyowa Pharma Chemical Co., Ltd. | 2026 | KIRIN - Kirin Holdings Company, Limited
Kyowa Hakko Bio Co., Ltd., a Kirin Holdings subsidiary, announced that the transfer of all shares of Kyowa Pharma Chemical Co., Ltd. to Dai Nippon Printing Co. was completed on October 1, 2026, with the impact already reflected in Kirin’s FY2026 consolidated …
2026-07-15 Regarding the Execution of the Share Transfer Agreement for Kyowa Pharma Chemical Co., Ltd. | 2026 | KIRIN - Kirin Holdings Company, Limited
Kyowa Hakko Bio, a Kirin Holdings subsidiary, has agreed to transfer its wholly owned subsidiary Kyowa Pharma Chemical to Dai Nippon Printing Co. to unlock growth potential, allowing Kyowa Pharma Chemical’s CDMO business to be developed under an optimal …
2026-10-01 Announcement Regarding Completion of Share Acquisition of KYOWA PHARMA CHEMICAL
DNP announces it has acquired all shares of KYOWA PHARMA CHEMICAL, making KYOWA PHARMA a consolidated subsidiary and planning to rename it DNP Pharma Chemical in Feb 2027; the combined group aims to become a one-stop CDMO spanning APIs to finished products and …
2026-09-28 「L.ラクティスプラズマ」の経鼻接種により上気道における抗ウイルス自然免疫記憶の形成を確認呼吸器ウイルス感染症に対する新たなワクチン開発への応用に期待 | 2026年 | KIRIN - キリンホールディングス株式会社
Kyowa Hakko Kirin (Kirin) reports that their L. lactis Plasma, via intranasal administration, activates antiviral innate immune genes and induces innate immune memory, suggesting potential for a broad, natural-immune-based vaccine approach against respiratory …
2026-10-05 塩野義製薬、希少疾患薬の米イントラバイオ買収　3100億円で - 日本経済新聞
Kyowa Hakko Bio (Kirin) is not mentioned as a partner or beneficiary in this article; the piece reports Shionogi’s acquisition of IntraBio for about $2 billion to expand its rare-disease drug portfolio, with plans to pursue global rights and commercialization …
2026-07-03 Announcement Regarding the Execution of a Share Purchase Agreement for the Acquisition of KYOWA PHARMA CHEMICAL CO., LTD. as a Wholly Owned Subsidiary
Dai Nippon Printing (DNP) is acquiring KYOWA PHARMA CHEMICAL CO., LTD. (KYOWA PHARMA) to make it a wholly owned subsidiary, with KYOWA HAKKO BIO CO., LTD. and Kirin Holdings Company, Limited (KYOWA HAKKO BIO’s parent) involved in the sale; the deal aims to …

Связи: владельцы, партнёры, аналоги

Владельцы и инвесторы 10

материнская	Kirin Holdings Company, Limited
дочерняя	Kyowa Pharma Chemical Co., Ltd
дочерняя	BioKyowa Inc
дочерняя	Shanghai Kyowa Amino Acid Co., Ltd
дочерняя	Thai Kyowa Biotechnologies Co., Ltd
дочерняя	Kyowa Hakko U.S.A., Inc
дочерняя	Kyowa Hakko Europe GmbH
дочерняя	Kyowa Hakko Bio Italia S.r.l
дочерняя	Kyowa Hakko Bio Singapore Pte. Ltd
дочерняя	Kyowa Hakko

Партнёры и сделки 2

сторона сделки	Dai Nippon Printing Co …Kyowa Hakko Bio Co., Ltd. completed the transfer of its subsidiary, Kyowa Pharma Chemical Co., Ltd., to Dai Nippon Printing Co., Ltd. on October 1, 2026.…
сторона сделки	Ltd.) …Kyowa Hakko Bio Co., Ltd. completed the transfer of its subsidiary, Kyowa Pharma Chemical Co., Ltd., to Dai Nippon Printing Co., Ltd. on October 1, 2026.…

Реквизиты и контакты

Контакты, руководители и юридические данные доступны участникам.

Войти как участник